Abstract

897TiP - A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
614P - Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
843O - Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
A Smith ... B.A Hadaschik
Annals of Oncology | VOL. 30
A Smith, et. al.A Smith ... B.A Hadaschik
01 Oct 2019
LBA50 - Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
E.Y Yu ... M.R Smith
Annals of Oncology | VOL. 30
E.Y Yu, et. al.E.Y Yu ... M.R Smith
01 Oct 2019
853P - ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
D.P Petrylak ... A Alcaraz
Annals of Oncology | VOL. 30
D.P Petrylak, et. al.D.P Petrylak ... A Alcaraz
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers